All Interventions

    Exosome Therapy

    Emerging
    Regenerative Medicine

    Cell-derived nanoparticles containing bioactive molecules that may provide regenerative benefits similar to stem cells.

    Evidence Summary

    4
    / 10Score
    Emerging
    Emerging Evidence

    First-in-human and preclinical data matured in 2025. A randomized, double-blind, dose-escalation trial (Journal of Translational Medicine, 2025; 41 patients, 45 knees, Kellgren–Lawrence grade 2–3) of intra-articular umbilical-cord MSC-derived exosomes reported statistically significant improvements in WOMAC pain, stiffness and physical function in the high-dose group (5×10^11 exosomes), with gains emerging by ~21 days and sustained to 9 months and no treatment-related adverse events — but there was no placebo or hyaluronic-acid control arm, so the effect versus standard care is unquantified. A 2025 systematic review and Bayesian network meta-analysis of 28 preclinical rodent studies (347 animals; Frontiers in Pharmacology) found large, consistent benefits on cartilage structure (OARSI, collagen II, aggrecan) and inflammatory markers (IL-6, IL-10). Human evidence remains early and largely uncontrolled. The U.S. FDA states there are currently no FDA-approved exosome products and has issued repeated warnings and warning letters (2019–2025) about unapproved exosome products; source and manufacturing quality vary widely. Investigational — an educational summary of published research, not a treatment claim.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Exosomes are cell-derived nanovesicles (~30–150 nm) that carry proteins, lipids and regulatory nucleic acids — notably microRNAs — from their parent cell (commonly mesenchymal stem cells). Taken up by recipient cells, they are thought to reproduce much of the paracrine, immunomodulatory and pro-regenerative signalling of stem cells without transplanting live cells: dampening inflammatory cytokines, supporting cartilage-matrix synthesis (collagen II, aggrecan) and modulating tissue-repair pathways.

    Who Is This For?

    Regenerative goals, anti-aging, tissue healing. Experimental with limited proven applications.

    Protocol & Dosing

    Dose

    Varies by source and indication. Typical: 10-50 billion exosomes per treatment.

    Frequency

    Single to monthly

    Duration

    Variable protocols

    Protocol Summary

    Delivered by local injection (e.g. intra-articular for joints) or IV infusion. In the 2025 knee-osteoarthritis trial, single intra-articular doses of 3–5×10^11 MSC-derived exosomes were studied, with the highest dose most effective. Dose, source (umbilical-cord, placental, or adipose MSC) and manufacturing quality vary widely and are not standardized; benefit and safety depend heavily on product quality and physician oversight.

    Latest Evidence

    2025: first human dose-escalation trial + preclinical meta-analysis

    In 2025 the first randomized, double-blind, dose-escalation trial of intra-articular umbilical-cord MSC-derived exosomes for knee osteoarthritis treated 41 patients (45 knees; Kellgren–Lawrence grade 2–3) across low, medium and high doses (3–5×10^11 exosomes). The high-dose group showed statistically significant improvements in WOMAC pain, stiffness and physical function, with benefits emerging by about 21 days and sustained to 9 months; liver and kidney markers and vital signs were unchanged and no treatment-related adverse events were reported. Because the trial had no placebo or hyaluronic-acid control arm, the effect versus standard care cannot be quantified. Separately, a 2025 systematic review and network meta-analysis of 28 preclinical rodent studies found large, consistent benefits on cartilage structure and inflammation (chart below).

    Exosome therapy is investigational. The U.S. FDA states there are currently no FDA-approved exosome products and has issued multiple warnings and warning letters (2019–2025) about unapproved exosome products marketed for orthopedic, neurological, cosmetic and other uses, citing quality and safety concerns and reports of serious adverse events. Source and manufacturing quality vary widely. This is an educational summary of published research, not medical advice or a treatment claim; any use should be under qualified physician supervision.

    Preclinical Evidence · Rodent Meta-Analysis

    Large effect sizes across cartilage and inflammation markers

    Pooled standardized mean differences (|SMD|) versus placebo, all favoring MSC-derived exosomes, from a 2025 systematic review and Bayesian network meta-analysis of 28 preclinical rodent knee-osteoarthritis studies (347 animals). Wang Z, et al., Frontiers in Pharmacology, 2025. Preclinical animal data only — not a substitute for human trials.

    Key references: Human umbilical cord MSC exosomes for knee osteoarthritis: preclinical to clinical — Journal of Translational Medicine (2025) · MSC-derived exosomes for knee osteoarthritis: systematic review & meta-analysis — Frontiers in Pharmacology (2025) · FDA Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes (2024)

    Interactions & Precautions

    Contraindications

    • Active infection
    • Active malignancy (theoretical)

    Potential Risks

    • •Limited human data
    • •Quality control challenges
    • •Regulatory uncertainty
    • •Unknown long-term effects

    Potential Side Effects

    Injection site reactions
    Unknown long-term effects

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Promising but early and investigational. The first human controlled-dose data (knee OA, 2025) are encouraging on safety and symptoms but lack a comparator arm; most efficacy evidence remains preclinical. No FDA-approved exosome products exist and regulatory enforcement is active — source, purity and manufacturing standards are critical. Use only within appropriate regulatory and consent frameworks, under qualified physician supervision.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$$$

    Accessibility

    Specialty clinics

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation